AFL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aflac Inc is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has introduced a new product that could drive future demand, the recent financial performance shows significant declines in revenue, net income, and EPS. Additionally, technical indicators and options data do not suggest a strong upward momentum. Analysts' ratings are mixed, and there is no recent Congress trading data to provide further confidence. For now, holding the stock or waiting for better entry points may be more prudent.
The MACD is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 52.374, and moving averages are converging, showing no clear trend. Key support is at 106.158, and resistance is at 110.024. Overall, the technical indicators suggest a lack of strong directional momentum.
Aflac introduced a new hybrid term life and long-term care product aimed at addressing growing demand for workplace financial stability solutions. Hedge funds have significantly increased their buying activity.
Insiders are selling heavily, with a 1011.95% increase in selling activity over the last month. Financial performance in Q4 2025 showed significant declines in revenue (-9.94%), net income (-27.50%), and EPS (-22.81%). Analysts have mixed ratings, with some lowering price targets and expressing concerns about sector headwinds.
In Q4 2025, revenue dropped to $4.87B (-9.94% YoY), net income fell to $1.38B (-27.50% YoY), and EPS declined to $2.64 (-22.81% YoY). Gross margin remained flat. Overall, the financials indicate a challenging quarter with declining profitability.
Analysts have mixed ratings on Aflac. Keefe Bruyette re-initiated coverage with a Market Perform rating and a $113 price target. Wells Fargo raised the price target to $118 but maintained an Equal Weight rating. Other firms like TD Cowen and Barclays lowered their price targets, citing sector headwinds. BofA maintained a Buy rating with a reduced price target of $120, while Raymond James remains optimistic with an Outperform rating and a $119 price target.
